Safety profiling of pioglitazone and telmisartan combination by sub-chronic toxicity study in rat
It has been reported that the major cause of mortality in diabetes is cardiovascular diseases and contribution of hypertension is significant in this context. Pioglitazone, a thiazolidinedione class of therapeutic agent is used to treat type 2 diabetes mellitus. Telmisartan, an angiotensin recepto...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English English |
| Published: |
Elsevier
2016
|
| Subjects: | |
| Online Access: | http://irep.iium.edu.my/52030/ http://irep.iium.edu.my/52030/ http://irep.iium.edu.my/52030/ http://irep.iium.edu.my/52030/1/Toxicity_Pio%20Tel_Pinaki%20paper.pdf http://irep.iium.edu.my/52030/7/52030-Safety%20profiling%20of%20pioglitazone%20and%20telmisartan%20combination%20by%20sub-chronic%20toxicity%20study%20in%20rat_SCOPUS.pdf |
| Summary: | It has been reported that the major cause of mortality in diabetes is cardiovascular diseases and
contribution of hypertension is significant in this context. Pioglitazone, a thiazolidinedione class of
therapeutic agent is used to treat type 2 diabetes mellitus. Telmisartan, an angiotensin receptor blocker
antihypertensive has been reported to have beneficial effect if co-administered with pioglitazone for the
management of diabetes complications. The present research work aims to evaluate the safety/toxicity
profile of this combination in rat model. The investigation was carried out after co-administering the
drugs to the rats for 28 days at three dose levels of 50, 100 and 150 mg/kg covering low to high dose
ranges. Various hematological and biochemical parameters were studied in addition to the histopathology
of the major organs in order to evaluate the toxicity profile of the combination. Absence of
mortality and histopathological changes as well as unaltered hematological and biochemical parameters
was observed. This preliminary investigation concludes that the combination of pioglitazone and telmisartan
can primarily be stated as safe in animals, even at the dose level which is several folds higher
than the intended human dose. Thus, this combination can be explored in future to develop a rational
therapy regimen to treat hypertensive diabetic patients. |
|---|